日時：	2024年8月1日（木）18：00～19：00
場所：	京都大学医生物学研究所　医生研２号館　１階セミナー室（104室） 1F Seminar room (104), Bldg. #2 of Institute for Life and Medical Sciences (LiME)
演者：	Dr. Sumit Chanda, PhD Professor, Immunology & Microbiology, Scripps Research; Principal Investigator, Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)
演題：	Building the plane while flying: Drug discovery during the COVID-19 pandemic

講演要旨

The emergence of SARS-CoV-2 as a global pandemic in 2019, which has tragically claimed nearly 7 million lives to date,
has underscored the urgent necessity for the development of antiviral therapies targeting viruses with pandemic potential.
In January 2020, we assembled a team of virologists, including researchers from the Sun, Garcia-Sastre, Yuan, and Yuen
laboratories, to investigate existing drugs that could be repurposed as antivirals for the novel coronavirus.
These collaborative efforts led to the identification of 21 known drugs that exhibited the capability to inhibit SARS-CoV-2
in vitro at concentrations believed to be achievable when administered to humans. Further research involved a
comprehensive characterization of one of these compounds, clofazimine (CFZ), which demonstrated significant antiviral
activity in vivo, both as a preventive measure and in a therapeutic context. CFZ was found to function through multiple
mechanisms, including the inhibition of helicase and spike-mediated fusion, and it displayed synergy with the RdRp
inhibitor remdesivir.
Although more potent direct-acting antivirals have been developed and approved for SARS-CoV-2, thereby reducing the
need for repurposed therapies, the importance of advancing additional antivirals for coronavirus infections and other viruses
with pandemic potential remains evident. To this end, we established the Center for Antiviral Medicines and Pandemic
Preparedness (CAMPP) as a member of the Antiviral Drug Discovery (AVIDD) consortium. These collaborative endeavors
have accelerated the development of novel inhibitors targeting SCV2 Mpro and RdRp, as well as inhibitors against helicase,
PLpro, and viral RNA translation. Furthermore, the Center has identified promising inhibitors for other viruses, such as
DENV, EBOV, and LASV, which are currently undergoing therapeutic development.
The collective efforts to develop novel vaccines and antivirals aimed at combating viruses with pandemic potential will
play a crucial role in ensuring that the world is better prepared for future pandemics.　　　（開催言語：英語 Language: English）

 

主催：
JSPS 研究拠点形成事業Core-to-Core Program「ウイルスの⼆⾯性の理解・活⽤のための国際研究拠点形成」
共同利⽤・共同研究拠点「ウイルス・幹細胞システム医生物学共同研究拠点」
共催：HiLung株式会社

世話人：京都大学医生物学研究所
RNAウイルス分野　朝長　啓造